reports
Applied Therapeutics Announces Key Leadership Appointments
Applied Therapeutics Announces Key Leadership Appointments Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhDDottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CABO CABLE ONE INC.
BUSE FIRST BUSEY CORPORATION
IRIX IRIDEX CORP.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
VRA VERA BRADLEY INC.
QTRX QUANTERIX CORPORATION
ULBI ULTRALIFE
DCTH DELCATH SYSTEMS
WHLR WHEELER REAL ESTATE INVESTMENT TRUST INC.
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
Applied Therapeutics Presents Full 12-Month Clinical Results and New T...
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically signifi...
Applied Therapeutics Reports First Quarter 2025 Financial Results
Applied Therapeutics Reports First Quarter 2025 Financial Results - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosemia and CMT-SORD Deficiency ongoing NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare d...
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract fo...
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that it will pre...
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financia...
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full yea...
Applied Therapeutics Files Form 12b-25 with the Securities and Exchang...
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b...
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Re...
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer Dr. Baumgartner will advance Applied’s preparation for upcoming regulatory interactions NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company’s executive leadership team and will be responsible for leading Applied’s global regulatory s...
- Jonathan Moreland
THFF FIRST FINANCIAL CORP. (INDIANA)
ORRF ORRSTOWN FINANCIAL SERVICES INC.
MPC MARATHON PETROLEUM CORPORATION
MGPI MGP INGREDIENTS INC.
DLY LYONDELLBASELL INDUSTRIES NV
FFIN FIRST FINANCIAL BANKSHARES INC
CIM CHIMERA INVESTMENT CORPORATION
CE CELANESE CORPORATION
TREE LENDINGTREE INC.
BWFG BANKWELL FINANCIAL GROUP
SNBR SLEEP NUMBER CORPORATION
TCPC BLACKROCK TCP CAPITAL CORP.
NFE NEW FORTRESS ENERGY
ZYME ZYMEWORKS INC.
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
UAN CVR PARTNERS LP
CMTG CLAROS MORTGAGE TRUST
ECAT INC.
EBC BLACKROCK ESG CAP ALLOCATION TR
MEGI EASTERN BANKSHARES INC
NE MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
SMRT NOBLE CORP (NEW)
SRBK SMARTRENT INC
NBBK SR BANCORP INC
BHRB NB BANCORP INC.
MXF BURKE HERBERT FINANCIAL SERVICES CORP
EVM THE MEXICO FUND
VG INC.
EATON VANCE INSD CALIF MUN BD FD
VENTURE GLOBAL INC.
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
ITCI INTRA-CELLULAR THERAPIES INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
FRPT FRESHPET INC
FFIN FIRST FINANCIAL BANKSHARES INC
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
CLRO CLEARONE
CINF CINCINNATI FINANCIAL CORPORATION
AKAM AKAMAI TECHNOLOGIES INC.
AFG AMERICAN FINANCIAL GROUP INC.
DGICA DONEGAL GROUP INC. CL A
CECE CECO ENVIRONMENTAL CORP.
OESX ORION ENERGY SYSTEMS INC.
NHC NATIONAL HEALTHCARE CORP.
PLBC PLUMAS BANCORP
JFR NUVEEN FLOATING RATE INCOME FUND
JELD JELD-WEN HOLDING INC.
CLF CLIFFS NATURAL RESOURCES INC.
VRNA VERONA PHARMA ADS
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
QNBC QNB CORP.
PCG PG &E CORPORATION
RCUS ARCUS BIOSCIENCES
REZI RESIDEO TECHNOLOGIES
CXDO INC.
CMTV CREXENDO
PRG COMMUNITY BANCORP INC. VT
VMEO PROG HOLDINGS
ETO INC.
ECAT VIMEO INC
MAIA EATON VANCE TAX ADV GBL DIV OPPTY
PFHC BLACKROCK ESG CAP ALLOCATION TR
ETG MAIA BIOTECHNOLOGY INC
EVT PROFRAC HLDG CORP
SSII EATON VANCE TAX ADV GLB DIN INC
ADVM EATON VANCE TAX ADVANTAGED DIVID IN
ISPO SS INNOVATIONS INTERNATIONAL INC
EVM ADVERUM BIOTECHNOLOGIES INC.
INSPIRATO INCORPORATED
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
PDFS PDF SOLUTIONS INC.
MTDR MATADOR RESOURCES COMPANY
FFIN FIRST FINANCIAL BANKSHARES INC
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
CINF CINCINNATI FINANCIAL CORPORATION
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
QNBC QNB CORP.
TXG 10X GENOMICS INC CLASS A
CMTV COMMUNITY BANCORP INC. VT
ECBK ECB BANCORP INC.
MAIA MAIA BIOTECHNOLOGY INC
ISPO INSPIRATO INCORPORATED
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President a...
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality Ms. Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industries NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceuti...
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Applied Therapeutics Appoints John H. Johnson as Executive Chairman Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana S...
Molecular Templates Announces Notice of Delisting and Failure to Satis...
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...
Molecular Templates Announces Receipt of Expected Notification of Defi...
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...
Applied Therapeutics Receives Complete Response Letter from U.S. FDA R...
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Gal...
Applied Therapeutics Reports Third Quarter 2024 Financial Results
Applied Therapeutics Reports Third Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD Deficiency under Accelerated Approval expected in early Q1 2025 NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates again...
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conf...
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California. A live webcast for this event will be accessible on the Events page under the Investor Relations...
Applied Therapeutics Provides Regulatory Update on Govorestat for the ...
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia - Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action date of November 28, 2024 NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.